Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts on Near Term Uotrends -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1108)	6/11/2009 11:16:52 AM
From: Jibacoa	Respond to of 1404

GENT continues doing well. <g> bigcharts.marketwatch.com bigcharts.marketwatch.com Last week it reported 1stQ results and provided 'Financial Highlights',<g> The Company’s financial statements are prepared using the Euro as its functional currency. On March 31, 2009, €1.00 = $1.3261. For the first quarter ended March 31, 2009 compared with the prior year’s first quarter: * Total revenues were €1.01 million, compared with €2.69 million resulting from the discontinuation of the sale of Prociclide and Noravid (both forms of Defibrotide) through Crinos S.p.A. in the Italian market. * Operating costs and expenses were €4.16 million, compared with €7.53 million * Research and development expenses, which are included in operating costs and expenses, were €1.45 million, compared with €3.61 million * Operating loss was €3.14 million, compared with €4.84 million * Net loss was €2.96 million, compared with €6.08 million * Basic and diluted net loss per share was €0.20 compared with €0.41 per share Cash and cash equivalents were €4.62 million compared with €11.49 million as of December 31, 2008. During the first quarter ended March 31, 2009, the Company made a final installment payment of €4.0 million to Crinos S.p.A. related to the acquisition of marketing authorizations and trademarks for Prociclide and Noravid. Clinical Update " At the end of the first quarter, Gentium announced preliminary top-line results from a Phase 2/3 European pediatric prevention clinical trial of Defibrotide at the Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) in Göteborg, Sweden. The results from this clinical trial demonstrated a 40% reduction in incidence of VOD within 30 days after stem cell transplantation (SCT) with a statistical P-value of 0.0539. In addition, the analysis of data pursuant to the protocol (patients who completed 30 days in the study), which included 164 patients in the prophylaxis arm and 169 patients in the control arm, showed a 43% reduction rate of the incidence of VOD within 30 days and achieved a statistical P-value of 0.0366. The data also demonstrated the excellent safety profile of Defibrotide showing no difference in adverse events between the prophylaxis and control arms. Subsequent to March 31, 2009, Defibrotide has become available on a named-patient basis throughout the European and Asia-Pacific markets. Defibrotide will be supplied by IDIS, a recognized leader in the management of named-patient programs. The product is being distributed to healthcare professionals for the treatment and prevention of veno-occlusive disease (VOD) post SCT. Through the named-patient program, Gentium is charging for the use of Defibrotide, but will continue to supply the product free-of-charge for use in clinical trials. “The preliminary pediatric prevention data presented at the EBMT support the continued development of Defibrotide to treat and prevent veno-occlusive disease,” stated Dr. Laura Ferro, CEO of Gentium S.p.A. “With no other treatment options available for these patients, we have already seen strong numbers in requests for Defibrotide through our named-patient program in Europe and Asia and our compassionate use program in the United States. We strongly believe this underscores and validates the unmet need and market potential for Defibrotide and remain hopeful that we will obtain regulatory approval for Defibrotide in Europe and the U.S.” “In a short five-week-period since the first sale of Defibrotide through the named-patient program in Europe and Asia-Pacific, we have generated over €676,000 in revenue,” stated Gary Gemignani, CFO of Gentium S.p.A. “We expect this program to generate cash flow that will allow us to operate beyond the end of this year.” “We are hopeful that this program along with the cost reduction measures already implemented will allow us greater flexibility as we continue to evaluate our financial and strategic options." Bernard

To: Jibacoa who wrote (1108)	6/11/2009 12:21:57 PM
From: Jibacoa	Read Replies (1) \| Respond to of 1404

ESLR continues the present UT with good volume. <g> But I don't like those UGs.<g> bigcharts.marketwatch.com It reported a loss in the 1stQ in spite of better revenues and Thomson estimates for 2009 are for a loss around $0.45/shr vs. $0.12 in 2008. But it is expected to report on the black in 2010 <g> It seems it could get to the $4 level and to test the $6 on a longer term basis, with some good news.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1108)	9/17/2009 7:46:34 PM
From: Jibacoa	Respond to of 1404

CPTC Has continued its recent UT. It already has a 300% gain this month.<g> Except for a penny drop on Sep 11, it is now up for the last 7 days,including today's 21% gain.The volume today of 11,798,995 was above its ADV. bigcharts.marketwatch.com The stock is starting to get off from the intermediate term DT coming from its Oct 2007 H at $2.16 But it still need a further up-move in order to get off from the longer DT coming from its Dec 2004 H at $6.36 <g> bigcharts.marketwatch.com Bernard